RT Journal Article
SR Electronic
T1 Incidence and prevalence of NMOSD in Australia and New Zealand
JF Journal of Neurology, Neurosurgery & Psychiatry
JO J Neurol Neurosurg Psychiatry
FD BMJ Publishing Group Ltd
SP 632
OP 638
DO 10.1136/jnnp-2016-314839
VO 88
IS 8
A1 Wajih Bukhari
A1 Kerri M Prain
A1 Patrick Waters
A1 Mark Woodhall
A1 Cullen M O‘Gorman
A1 Laura Clarke
A1 Roger A Silvestrini
A1 Christine S Bundell
A1 David Abernethy
A1 Sandeep Bhuta
A1 Stefan Blum
A1 Mike Boggild
A1 Karyn Boundy
A1 Bruce J Brew
A1 Matthew Brown
A1 Wallace J Brownlee
A1 Helmut Butzkueven
A1 William M Carroll
A1 Celia Chen
A1 Alan Coulthard
A1 Russell C Dale
A1 Chandi Das
A1 Keith Dear
A1 Marzena J Fabis-Pedrini
A1 David Fulcher
A1 David Gillis
A1 Simon Hawke
A1 Robert Heard
A1 Andrew P D Henderson
A1 Saman Heshmat
A1 Suzanne Hodgkinson
A1 Sofia Jimenez-Sanchez
A1 Trevor Killpatrick
A1 John King
A1 Christopher Kneebone
A1 Andrew J Kornberg
A1 Jeannette Lechner-Scott
A1 Ming-Wei Lin
A1 Christpher Lynch
A1 Richard Macdonell
A1 Deborah F Mason
A1 Pamela A McCombe
A1 Michael P Pender
A1 Jennifer A Pereira
A1 John D Pollard
A1 Stephen W Reddel
A1 Cameron Shaw
A1 Judith Spies
A1 James Stankovich
A1 Ian Sutton
A1 Steve Vucic
A1 Michael Walsh
A1 Richard C Wong
A1 Eppie M Yiu
A1 Michael H Barnett
A1 Allan G Kermode
A1 Mark P Marriott
A1 John D E Parratt
A1 Mark Slee
A1 Bruce V Taylor
A1 Ernest Willoughby
A1 Robert J Wilson
A1 Angela Vincent
A1 Simon A Broadley
YR 2017
UL http://jnnp.bmj.com/content/88/8/632.abstract
AB Objectives We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Australia and New Zealand to establish incidence and prevalence across the region and in populations of differing ancestry.Background NMOSD is a recently defined demyelinating disease of the central nervous system (CNS). The incidence and prevalence of NMOSD in Australia and New Zealand has not been established.Methods Centres managing patients with demyelinating disease of the CNS across Australia and New Zealand reported patients with clinical and laboratory features that were suspicious for NMOSD. Testing for aquaporin 4 antibodies was undertaken in all suspected cases. From this group, cases were identified who fulfilled the 2015 Wingerchuk diagnostic criteria for NMOSD. A capture–recapture methodology was used to estimate incidence and prevalence, based on additional laboratory identified cases.Results NMOSD was confirmed in 81/170 (48%) cases referred. Capture–recapture analysis gave an adjusted incidence estimate of 0.37 (95% CI 0.35 to 0.39) per million per year and a prevalence estimate for NMOSD of 0.70 (95% CI 0.61 to 0.78) per 100 000. NMOSD was three times more common in the Asian population (1.57 (95% CI 1.15 to 1.98) per 100 000) compared with the remainder of the population (0.57 (95% CI 0.50 to 0.65) per 100 000). The latitudinal gradient evident in multiple sclerosis was not seen in NMOSD.Conclusions NMOSD incidence and prevalence in Australia and New Zealand are comparable with figures from other populations of largely European ancestry. We found NMOSD to be more common in the population with Asian ancestry.